CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Aprepitant

Last Updated: August 29, 2007
Result type: Reports
Project Number: S0109
Product Line: Reimbursement Review

Generic Name: Aprepitant

Brand Name: Emend

Manufacturer: Merck Frosst Canada Ltd.

Indications: Nausea and Vomiting, Chemotherapy induced

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: February 20, 2008

Recommendation Type: List with clinical criteria and/or conditions